Minjung Wang
Seoul National University Bundang Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Minjung Wang.
Alzheimers & Dementia | 2017
Min Jae Baek; Karyeong Kim; Young Ho Park; YoungHee Chang; Minjung Wang; SangYun Kim
over time. Even among those (n1⁄4282) we have previously identified as ‘false positive’ MCI diagnostic errors in ADNI (Edmonds et al., 2015), only 15 of the 24 ADNI reverters were baseline ‘false positives’, thereby missing 94.7% of participants in whom a cognitively normal diagnosis appears better justified based on neuropsychological performance, normal biomarkers, lack of cortical thinning, and low progression rates. Additionally, compared to ADNI, the NP criteria identified more new MCI cases and greater CSF reductions in b-amyloid in normal-to-MCI individuals, consistent with their cognitive decline. We conclude that ADNI has an artificially low reversion rate (3%) even when compared to metaanalytic reversion rates (24%) based largely on conventional criteria (Malek-Ahmadi, 2016).
Alzheimers & Dementia | 2017
SangYun Kim; Seong Soo A. An; Byoung-sub Lee; Ji Sun Yu; Kuntaek Lim; Gwang Je Kim; Ryan Lee; Shinwon Kim; Sungmin Kang; Young Ho Park; Minjung Wang; Young Chul Youn
Model 1 Per g/dL increase (n1⁄4233) 0.11(0.03,0.18) -0.11 (-0.18, -0.04) -0.12 (-0.18, -0.05) >14 g/dL (n1⁄475) Reference Reference Reference 12-14 g/dL (n1⁄484) 0.18 (-0.11,0.48) -0.05 (-0.33, 0.23) 0.10 (-0.17, 0.37) <12 g/dL (n1⁄474) -0.34 (-0.65, -0.02) 0.32 (0.03, 0.61) 0.36 (0.08, 0.64) P for trend 0.038 0.031 0.013 Model 2 Per g/dL increase (n1⁄4233) 0.11(0.03,0.19) -0.11 (-0.19, -0.04) -0.08 (-0.14, -0.01) >14 g/dL (n1⁄475) Reference Reference Reference 12-14 g/dL (n1⁄484) 0.14 (-0.16,0.44) -0.02 (-0.30, 0.26) 0.09 (-0.18, 0.37) <12 g/dL (n1⁄474) -0.68 (-0.59, -0.01) 0.30 (-0.01,0.62) 0.21 (-0.08, 0.52) P for trend 0.064 0.067 0.163
Alzheimers & Dementia | 2017
Eva Bagyinszky; Vo Van Giau; Kyu Hwan Shim; Minjung Wang; Young Ho Park; YoungSoon Yang; Kyusik Yun; Young Chul Youn; Seong Soo A. An; SangYun Kim
Figure 2. Comparison of tau SUVR levels in cognitively unimpaired (Unimp) HIV+ vs. cognitively impaired (lmp) HIV+ subjects. Levels are shown in the entorhinal, inferior temporal (inftemp), medial orbitofrontal (medorbfrntl) and anterior cingulate (ant cc) cortex, and in the precuneus and insula. Figure 3. Comparison of tau SUVR levels in entorhinal cortex plotted against nadir CD4 cell count for HIV+ subjects (N1⁄417). The p-value for a linear relationship is 0.57. Poster Presentations: Tuesday, July 18, 2017 P965
Alzheimers & Dementia | 2016
Eva Bagyinszky; Vo Van Giau; Young Ho Park; Minjung Wang; So Young Park; Jae-Won Jang; Young Chul Youn; Seong Soo A. An; SangYun Kim
Eva Bagyinszky, Vo Van Giau, Young Ho Park, Minjung Wang, So Young Park, Jae Won Jang, Young Chul Youn, Seong Soo An, SangYun Kim, Gachon University, Seongnam, South Korea; Gachon University, Seongnam, South Korea; Clinical Neuroscience Center, Seoul National University Bundang Hospital, Seongnam, Republic of Korea; 4 Clinical Neuroscience Center, Seoul National University Bundang Hospital, Seongnam, South Korea; 5 Kangwon National University, Chuncheon, Republic of Korea; Chung-Ang University Hospital, Seoul, South Korea; Seoul National University Bundang Hospital, Seongnam, South Korea; 8 Seoul National University Bundang Hospital, Seongnam, Republic of Korea. Contact e-mail: [email protected]
Alzheimers & Dementia | 2015
Eva Bagyinszky; Young Ho Park; So Young Park; Minjung Wang; Young Chul Youn; Seong Soo A. An; SangYun Kim
the Assessment of Neuropsychological Status (RBANS) was also evaluated for the PREVENT-AD cohort. Results: In the QFP, the 299Gly allele was present in 6.3% of LOAD cases and 10.7% of aged-matched control subjects (p 0.005). Healthy subjects enrolled in the PREVENT-AD study (with a first-degree family history of AD) were positive for the 299Gly allele in a proportion of 12.5%. In ADNI, the 299Gly allele was detected in 9.5% of AD cases, 9.9% ofMCI patients and 11.2% of control subjects (baseline diagnostic, p 0.05). Although not associated with the disease in the latter population, the 299Gly allele significantly correlated with higher CSF APOE levels measured in MCI patients. In unaffected subjects from the PREVENT-AD cohort, the 299Gly allele was significantly associated with enhanced cortical thickness and a higher RBANS visuospatial score. Conclusions: The presence of the 299Gly allele is clearly associated with neuroprotection. Targeting TLR4 signaling pathway could be considered for pharmacological intervention to prevent Alzheimer’s disease.
Alzheimers & Dementia | 2017
Eva Bagyinszky; Vo Van Giau; Kyu Hwan Shim; Young Ho Park; Minjung Wang; Seong Soo A. An; SangYun Kim
Alzheimers & Dementia | 2017
Eva Bagyinszky; Vo Van Giau; Kyu Hwan Shim; Minjung Wang; Young Ho Park; Seong Soo A. An; SangYun Kim
Alzheimers & Dementia | 2016
Eva Bagyinszky; Vo Van Giau; So Young Park; Minjung Wang; Young Ho Park; Jae-Won Jang; Young Chul Youn; Seong Soo A. An; SangYun Kim
Alzheimers & Dementia | 2016
Eva Bagyinszky; Vo Van Giau; Jae-Won Jang; Minjung Wang; So Young Park; Seong Soo A. An; Young Chul Youn; Sang Yun Kim
Alzheimers & Dementia | 2016
Jee-young Han; SangYun Kim; Young Ho Park; Minjung Wang; SangHak Yi; Soyeon Ahn